Answers are grounded in this paper and cite their sources.
Background: Diabetes mellitus and hypertension require long-term treatment, regular monitoring and sustained medication adherence. Drug-related problems and inadequate patient education may affect treatment outcomes and healthcare utilization. Clinical pharmacists may support chronic disease management through medication review, counselling and follow-up. Objective: To evaluate the impact of clinical pharmacist intervention on hospital readmission, medication adherence, drug-related problems, patient satisfaction and healthcare costs among patients with diabetes mellitus and hypertension. Materials and methods: A six-month hospital-based study was conducted in the General Medicine department of KIMS Hospital and Research Centre, Bengaluru. The thesis reports 100 participants, with 50 in the control group and 50 in the intervention group. Interventions included medication review, medication optimization, patient education, discharge counselling, lifestyle modification counselling and follow-up. Outcomes included readmission, medication adherence, drug-related problems, satisfaction with counselling and selected direct medical costs. Results: At one-month follow-up, readmission was reported in 3% of the control group and 1% of the intervention group. At two months, the results table recorded good medication adherence in 48% of the control group and 49% of the intervention group. In the intervention group, dose too high/low (38%) and cost issues (24%) were the most frequently listed drug-related problems. Patient counselling was rated excellent by (69.4%) of intervention-group respondents. Cost measures varied between groups and did not show a consistent reduction in the intervention group. Conclusion: The study findings suggest that clinical pharmacist involvement can provide medication review and counselling support and may be associated with a small difference in readmission and medication adherence outcomes. The available results do not establish statistically significant reductions in readmissions or overall healthcare costs. Larger studies with complete, internally consistent data and appropriate statistical testing are required.
No takes yet. Share an insight, caveat, or question.
S. et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: